<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, March 30, 2018 (HealthDay News) — The office-based, eight-item Montreal Parkinson Risk of Dementia Scale is a valid predictor of development of dementia, according to a study published online March 26 in JAMA Neurology<\/i>.<\/p>\n
Benjamin K. Dawson, from McGill University in Montreal, and colleagues conducted a multicenter study using four diverse Parkinson’s disease cohorts with a prospective 4.4-year follow-up to examine the predictive validity of the Montreal Parkinson Risk of Dementia Scale. A total of 717 patients with Parkinson’s disease were recruited; 607 were dementia-free at baseline and followed for one year or more.<\/p>\n
The researchers found that all eight items of the Montreal Parkinson Risk of Dementia Scale independently predicted the development of dementia (significant at the 5 percent level). In the high-risk group (score >5) the annual conversion rate to dementia was 14.9 percent, compared with 5.8 and 0.6 percent in the intermediate- (score, 4 to 5) and low-risk (score, 0 to 3) groups. Across all cohorts, the overall predictive validity by the area under the receiver operator characteristic curve was 0.877. Sensitivity was 77.1 percent and specificity 87.2 percent for a cut-off of 4 or greater, with positive and negative predictive values of 43.9 and 96.7 percent, respectively; positive and negative likelihood ratios were 5.94 and 0.26, respectively. There were correlations for scale results with makers of Alzheimer’s pathology and neuropsychological test results.<\/p>\n
“Future studies using head-to-head comparisons or refinement of weighting would be of interest,” the authors write.<\/p>\n
One author disclosed financial ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n